<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The synthesis and pharmacological characterisation of (1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1H-<z:chebi fb="0" ids="16069">imidazol</z:chebi>-2-yl)-<z:chebi fb="0" ids="16830">methanamine</z:chebi> and its derivatives in Pt(II) complexes are described </plain></SENT>
<SENT sid="1" pm="."><plain>Six out of eleven new Pt(II) complexes showed a significant cytotoxic effect on NCI-H460 <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> cell line with EC50 values between 1.1 and 0.115mM, determined by <z:chebi fb="0" ids="53233">MTT</z:chebi> assay </plain></SENT>
<SENT sid="2" pm="."><plain>Compound Pt-4a showed a particularly more potent cytotoxic effect than the previously described Pt(II) complex with <z:chebi fb="0" ids="30351">2,2'-bipyridine</z:chebi>, [Pt(<z:chebi fb="0" ids="30351">bpy</z:chebi>)<z:chebi fb="0" ids="29413">Cl2</z:chebi>], with an EC50 value equal to 172.7μM versus 726.5μM respectively, and similar potency of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> (EC50=78.3μM) in NCI-H460 cell line </plain></SENT>
<SENT sid="3" pm="."><plain>The determination of the intracellular and DNA-bound concentrations of (195)Pt, as marker of the presence of the complexes, showed that the cytotoxic compound Pt-4a readily diffused into the cells to a similar extent of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and directly interacted with the nuclear DNA </plain></SENT>
<SENT sid="4" pm="."><plain>Pt-4a induced both p53 and p21(Waf) expression in NCI-H460 cells similar to <z:chebi fb="2" ids="27899">cisplatin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>A direct comparison of the cytotoxic effect between compound Pt-4a and <z:chebi fb="2" ids="27899">cisplatin</z:chebi> on 12 different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines demonstrated that compound Pt-4a was in general less potent than <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, but it had a comparable cytotoxic effect on <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> NCI-H460 cells, and the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells HCT-15 and HCT-116 </plain></SENT>
<SENT sid="6" pm="."><plain>Altogether, these results suggested that the Pt(II) complex with 1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1H-<z:chebi fb="0" ids="16069">imidazol</z:chebi>-2-yl)-<z:chebi fb="0" ids="16830">methanamine</z:chebi> (compound Pt-4a), displayed a significant cytotoxic activity in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly to <z:chebi fb="2" ids="27899">cisplatin</z:chebi> this compound interacts with nuclear DNA and induces both p53 and p21(waf), and thus it represents an interesting starting point for future optimisation of new Pt(II) complexes forming DNA adducts </plain></SENT>
</text></document>